Significant Effect of APOE Epsilon 4 Genotype on the Risk of Dementia in Alzheimer's Disease and Mortality in Persons with Down Syndrome

Overview

Journal Int J Geriatr Psychiatry

Specialties Geriatrics
Psychiatry

Date 2008 May 9

PMID 18464295

Citations 45

Authors

V P Prasher

S G Sajith

S D Rees

A Patel

S Tewari

N Schupf

W B Zigman

Affiliations

Soon will be listed here.

Abstract

Objective: Virtually all adults with Down syndrome (DS) have neuropathological manifestations of Dementia in Alzheimer's disease (DAD) but not all develop clinical psychopathology. The effect of allelic variants of Apolipoprotein (APOE) gene in development and progression of DAD and mortality in persons with DS is examined.

Methods: Recruited participants with DS underwent two to 14 sequential assessments over a follow up period of 6 years on average and their APOE genotype determined. Dementia status was confirmed as recommended by the Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability.

Results: APOE genotype results were available for 252 individuals. Participants with APOE epsilon 4 allele had significantly higher risk of developing DAD (HR = 1.8, 95% CI: 1.12-2.79), had an earlier onset of DAD (55.0 vs 57.0 years; p = 0.0027) and a more rapid progression to death compared with participants with epsilon 3 allele (4.2 years vs. 5.4 years, respectively, p = 0.048). In non-demented persons with DS, epsilon 4 allele was associated with earlier death by 17 years (mean survival age, 55.7 vs. 72.7 years; HR = 5.9, 95% CI: 1.7-21.3).

Conclusions: This study highlights the relationship of APOE genotype to morbidity and mortality in persons with DS which has important clinical implications. We recommend screening for APOE genotype in persons with DS to identify those at risk of DAD and premature death. Further research is required to investigate the underlying reasons for the early mortality in non-demented DS persons with an epsilon 4 allele.

Citing Articles

Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer's disease.

Miyoshi E, Morabito S, Henningfield C, Das S, Rahimzadeh N, Kiani Shabestari S Nat Genet. 2024; 56(12):2704-2717.

PMID: 39578645 PMC: 11631771. DOI: 10.1038/s41588-024-01961-x.

Altered Brain Cholesterol Machinery in a Down Syndrome Mouse Model: A Possible Common Feature with Alzheimer's Disease.

Staurenghi E, Testa G, Leoni V, Cecci R, Floro L, Giannelli S Antioxidants (Basel). 2024; 13(4).

PMID: 38671883 PMC: 11047305. DOI: 10.3390/antiox13040435.

Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.

Gorijala P, Aslam M, Dang L, Xicota L, Fernandez M, Sung Y Alzheimers Dement. 2023; 20(2):1038-1049.

PMID: 37855447 PMC: 10916941. DOI: 10.1002/alz.13506.

Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.

Fleming V, Hom C, Clare I, Hurd-Thomas S, Krinsky-McHale S, Handen B Int Rev Res Dev Disabil. 2023; 62:227-263.

PMID: 37396708 PMC: 10312212. DOI: 10.1016/bs.irrdd.2022.05.006.

Aβ and tau prions feature in the neuropathogenesis of Down syndrome.

Condello C, Maxwell A, Castillo E, Aoyagi A, Graff C, Ingelsson M Proc Natl Acad Sci U S A. 2022; 119(46):e2212954119.

PMID: 36343257 PMC: 9674250. DOI: 10.1073/pnas.2212954119.

References

Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E . Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. Eur Neurol. 1998; 39(4):234-7. DOI: 10.1159/000007940. View

Prasher V, Chowdhury T, Rowe B, Bain S . ApoE genotype and Alzheimer's disease in adults with Down syndrome: meta-analysis. Am J Ment Retard. 1997; 102(2):103-10. DOI: 10.1352/0895-8017(1997)102<0103:AGAADI>2.0.CO;2. View

van Duijn C, de Knijff P, Wehnert A, De Voecht J, Bronzova J, Havekes L . The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol. 1995; 37(5):605-10. DOI: 10.1002/ana.410370510. View

Roses A, Saunders A . APOE is a major susceptibility gene for Alzheimer's disease. Curr Opin Biotechnol. 1994; 5(6):663-7. DOI: 10.1016/0958-1669(94)90091-4. View

van Gool W, Evenhuis H, van Duijn C . A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing. Ann Neurol. 1995; 38(2):225-30. DOI: 10.1002/ana.410380215. View

Royston M, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R . Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport. 1994; 5(18):2583-5. DOI: 10.1097/00001756-199412000-00044. View

Ewbank D . Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol. 2002; 22(2):146-55. DOI: 10.1002/gepi.0164. View

Khachaturian A, Corcoran C, Mayer L, Zandi P, Breitner J . Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry. 2004; 61(5):518-24. DOI: 10.1001/archpsyc.61.5.518. View

Houlden H, Greenwood R . Apolipoprotein E4 and traumatic brain injury. J Neurol Neurosurg Psychiatry. 2006; 77(10):1106-7. PMC: 2077546. DOI: 10.1136/jnnp.2006.095513. View

10.

Krinsky-McHale S, Devenny D, Gu H, Jenkins E, Kittler P, Murty V . Successful aging in a 70-year-old man with down syndrome: a case study. Intellect Dev Disabil. 2008; 46(3):215-28. DOI: 10.1352/2008.46:215-228. View

11.

Meyer M, Tschanz J, Norton M, Welsh-Bohmer K, Steffens D, Wyse B . APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet. 1998; 19(4):321-2. DOI: 10.1038/1206. View

12.

Schupf N, Sergievsky G . Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry. 2002; 180:405-10. DOI: 10.1192/bjp.180.5.405. View

13.

Wisniewski K, Wisniewski H, Wen G . Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985; 17(3):278-82. DOI: 10.1002/ana.410170310. View

14.

Schupf N, Kapell D, Lee J, Zigman W, Canto B, Tycko B . Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome. Ann Neurol. 1996; 40(5):799-801. DOI: 10.1002/ana.410400518. View

15.

Forno G, Carson K, Brookmeyer R, Troncoso J, Kawas C, Brandt J . APOE genotype and survival in men and women with Alzheimer's disease. Neurology. 2002; 58(7):1045-50. DOI: 10.1212/wnl.58.7.1045. View

16.

Aylward E, Burt D, Thorpe L, Lai F, Dalton A . Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res. 1997; 41 ( Pt 2):152-64. DOI: 10.1111/j.1365-2788.1997.tb00692.x. View

17.

Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, Mayeux R . Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology. 1998; 50(4):991-5. DOI: 10.1212/wnl.50.4.991. View

18.

Mann D . Alzheimer's disease and Down's syndrome. Histopathology. 1988; 13(2):125-37. DOI: 10.1111/j.1365-2559.1988.tb02018.x. View

19.

Yang Q, Rasmussen S, Friedman J . Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002; 359(9311):1019-25. DOI: 10.1016/s0140-6736(02)08092-3. View

20.

Dupuy A, Mas E, Ritchie K, Descomps B, Badiou S, Cristol J . The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology. 2001; 47(4):213-8. DOI: 10.1159/000052801. View